MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

Preclinical data supports the advancement of oral Ketamir-2 as a safe, next-generation alternative to ketamine, with ongoing momentum in Phase I clinical trial enrollment MIAMI, FL / ACCESS Newswire / May 6, 2025 / MIRA Pharmaceuticals, Inc. …
Jetzt den vollständigen Artikel lesen